Chronic administration of infliximab (TNF-α inhibitor) decreases depression and anxiety-like behaviour in rat model of chronic mild stress

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 5, 2013, Pages 335-340

  Karson, Ayşe ^a   Demirtaş, Tuǧçe ^a   Bayramgürler, Dilek ^a   Balci, Fuat ^b   Utkan, Tijen ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b KOÇ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; SODIUM CHLORIDE; SUCROSE;

ANIMAL EXPERIMENT; ANXIETY; ANXIETY DISORDER; ARTICLE; CHRONIC MILD STRESS; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; ELEVATED PLUS MAZE TEST; FORCED SWIMMING TEST; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PERSONALITY TEST; PRIORITY JOURNAL; RAT; SUCROSE PREFERENCE TEST; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANXIETY; BEHAVIOR, ANIMAL; CHRONIC DISEASE; DEPRESSION; DISEASE MODELS, ANIMAL; FOOD PREFERENCES; MALE; MAZE LEARNING; MOTOR ACTIVITY; RATS; RATS, WISTAR; STRESS, PHYSIOLOGICAL; SUCROSE; SWIMMING;

RATTUS;

EID: 84876443867     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12037     Document Type: Article

References (53)

1. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009;24:27-53.
2. Lee S, Jeong J, Kwak Y, Park SK. Depression research: where are we now? Mol Brain 2010;10:3-8.
3. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:722-9.
4. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764-85.
5. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-41.
6. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171-86.
7. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57.
8. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-52.
9. Pollak Y, Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol 2002;5:389-99.
10. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon- alpha. Biol Psychiatry 2006;56:819-24.
11. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 2003;170:429-33.
12. Myint AM, Leonard BE, Steinbusch HW, Kim YK. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 2005;88:167-73.
13. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 2006;6:903-7.
14. Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009;42:182-8.
15. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001;11:203-8.
16. Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep. 2008;10:258-64.
17. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 2009;15:1105-18.
18. Rieder E, Tausk F. Psoriasis, a model of dermatologic psychosomatic disease: psychiatric implications and treatments. Int J Dermatol 2012;51:12-26.
19. Quan N. Immune-to-brain signaling: how important are the blood-brain barrier-independent pathways? Mol Neurobiol 2008;37:142-52.
20. Banks WA, Erickson MA. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 2010;37:26-32.
21. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35.
22. Bassukas ID, Hyphantis T, Gamvroulia C, Gaitanis G, Mavreas V. Infliximab for patients with plaque psoriasis and severe psychiatric comorbidity. J Eur Acad Dermatol Venereol 2008;22:257-8.
23. Yip L, Harrison S, Foley P. Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression. Australas J Dermatol 2008;49:250-1.
24. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010;62:812-8.
25. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 1997;134:319-29.
26. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90-110.
27. Vitale G, Ruggieri V, Filaferro M, Frigeri C, Alboni S, Tascedda F et al. Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology 2009;207:173-89.
28. Wu X, Alberico SL, Moges H, De TaboadaL, Tedford CE, Anders JJ. Pulsed light irradiation improves behavioral outcome in a rat model of chronic mild stress. Lasers Surg Med 2012;44:227-32.
29. Feng SF, Shi TY, Fan Y, Wang WN, Chen YC, Tan QR. Long-lasting effects of chronic rTMS to treat chronic rodent model of depression. Behav Brain Res 2012;232:245-51.
30. Zhang Y, Gu F, Chen J, Dong W. Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in UCMS rat. Brain Res 2010;1366:141-8.
31. Schaalan MF, Nassar NN. Effects of octreotide in chronically mild stressed rats: possible role of immune and oxidative stress pathways. Neurochem Res 2011;36:1717-23.
32. Farooq RK, Isingrini E, Tanti A, Le Guisquet AM, Arlicot N, Minier F et al. Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation? Behav Brain Res 2012;231:130-7.
33. http://reference.medscape.com/drug/remicade-infliximab-343202.
34. Triantafillidis JK, Papalois AE, Parasi A, Anagnostakis E, Burnazos S, Gikas A et al. Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. World J Gastroenterol 2005;11:6843-7.
35. Güzel A, Günaydin M, Güzel A, Alaçam H, Murat N, Gacar A et al. Infliximab attenuates activated charcoal and polyethylene glycol aspiration-induced lung injury in rats. Exp Lung Res 2012;38:147-56.
36. Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992;16:525-34.
37. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatment. Nature 1977;266:730-2.
38. Sarkisova KY, Kuznetsova GD, Kulikov MA, van Luijtelaar G. Spike-wave discharges are necessary for the expression of behavioral depression-like symptoms. Epilepsia 2010;51:146-60.
39. Hattori S, Hashimoto R, Miyakawa T, Yamanaka H, Maeno H, Wada K et al. Enriched environments influence depression-related behavior in adult mice and the survival of newborn cells in their hippocampi. Behav Brain Res 2007;180:69-76.
40. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002;65:33-8.
41. Vécsei L, Beal MF. Influence of kynurenine treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats. Pharmacol Biochem Behav 1990;37:71-6.
42. Lapin IP, Mutovkina LG, Ryzov IV, Mirzaev S. Anxiogenic activity of quinolinic acid and kynurenine in the social interaction test in mice. J Psychopharmacol 1996;10:246-9.
43. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 2011;21:961-6.
44. Luheshi GN, Bluthé RM, Rushforth D, Mulcahy N, Konsman JP, Goldbach M et al. Vagotomy attenuates the behavioural but not the pyrogenic effects of interleukin-1 in rats. Auton Neurosci 2000;85:127-32.
45. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 2012;83:495-502.
46. Sharma HS, Ali SF, Tian ZR, Hussain SM, Schlager JJ, Sjöquist PO et al. Chronic treatment with nanoparticles exacerbate hyperthermia induced blood-brain barrier breakdown, cognitive dysfunction and brain pathology in the rat. Neuroprotective effects of nanowired-antioxidant compound H-290/51. J Nanosci Nanotechnol 2009;9:5073-90.
47. de Klerk OL, Bosker FJ, Willemsen AT, Van Waarde A, Visser AK, de Jager T et al. Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. J Psychopharmacol 2010;24:1237-42.
48. Bessa JM, Mesquita AR, Oliveira M, Pêgo JM, Cerqueira JJ, Palha JA et al. A trans-dimensional approach to the behavioral aspects of depression. Front Behav Neurosci 2009;3:1-7.
49. Li Y, Zheng X, Liang J, Peng Y. Coexistence of anhedonia and anxiety-independent increased novelty-seeking behavior in the chronic mild stress model of depression. Behav Processes 2010;83:331-9.
50. Gimsa U, Kanitz E, Otten W, Tuchscherer M, Tuchscherer A, Ibrahim SM. Tumour necrosis factor receptor deficiency alters anxiety-like behavioural and neuroendocrine stress responses of mice. Cytokine 2012;59:72-8.
51. Connor TJ, Song C, Leonard BE, Merali Z, Anisman H. An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience 1998;84:923-33.
52. Patel A, Siegel A, Zalcman SS. Lack of aggression and anxiolytic-like behavior in TNF receptor (TNF-R1 and TNF-R2) deficient mice. Brain Behav Immun 2010;24:1276-80.
53. Prager G, Hadamitzky M, Engler A, Doenlen R, Wirth T, Pacheco-López G et al. Amygdaloid Signature of Peripheral Immune Activation by Bacterial Lipopolysaccharide or Staphylococcal Enterotoxin B. J Neuroimmune Pharmacol 2012; (in press); DOI: 10.1007/s11481-012-9373-0.